Analysts expect Madrigal Pharmaceuticals, Inc. to report revenue of 458.63 M for Q4 26, against a range of 436.54 M to 480.72 M. The most recent reported quarter, Q3 26, came in at 431.30 M, a 12.7% beat against the 382.58 M consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 103.32 M | 137.25 M | 212.80 M | 287.27 M | 321.10 M | 311.34 M | 364.30 M | 431.30 M | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | 109.38 M | 122.53 M | 178.47 M | 289.97 M | 329.26 M | 330.43 M | 369.59 M | 404.98 M | 480.72 M | 461.43 M | 532.27 M | 649.65 M | 680.56 M | 679.01 M | 675.50 M | 857.81 M | |||||||||
| Low Estimate | 102.11 M | 113.73 M | 152.15 M | 239.29 M | 280.25 M | 286.88 M | 314.09 M | 360.18 M | 436.54 M | 392.74 M | 444.02 M | 577.09 M | 600.58 M | 620.65 M | 618.36 M | 717.41 M | |||||||||
| Consensus Estimate | 105.75 M | 118.13 M | 165.31 M | 264.63 M | 304.76 M | 308.65 M | 341.84 M | 382.58 M | 458.63 M | 427.09 M | 488.14 M | 613.37 M | 640.57 M | 649.83 M | 646.93 M | 787.61 M |
Analysts expect Madrigal Pharmaceuticals, Inc. to report earnings per share of 1.05 for Q4 26, against a range of 0.97 to 1.13. The most recent reported quarter, Q3 26, came in at 1.83, a 305.6% beat against the -0.89 consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -2.71 | -3.32 | -1.90 | -5.08 | -2.57 | -3.25 | -1.99 | 1.83 | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | -3.85 | -3.74 | -3.20 | -2.32 | -0.87 | -4.19 | -2.26 | -0.83 | 1.13 | -0.09 | 0.95 | 2.29 | 3.31 | 3.60 | 4.95 | 6.19 | |||||||||
| Low Estimate | -4.35 | -4.00 | -3.54 | -2.52 | -0.97 | -4.45 | -2.76 | -0.95 | 0.97 | -0.11 | 0.81 | 2.01 | 2.83 | 3.14 | 4.31 | 5.11 | |||||||||
| Consensus Estimate | -4.10 | -3.87 | -3.37 | -2.42 | -0.92 | -4.32 | -2.51 | -0.89 | 1.05 | -0.10 | 0.88 | 2.15 | 3.07 | 3.37 | 4.63 | 5.65 |
Pull Wall Street consensus for Madrigal Pharmaceuticals, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=MDGL&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "MDGL", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=MDGL&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();